Helius Medical Technologies Inc. logo

Helius Medical Technologies Inc. (HSDT)

Market Closed
15 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
7. 47
+0.12
+1.63%
$
55.54M Market Cap
- P/E Ratio
0% Div Yield
55,245 Volume
-16.71 Eps
$ 7.35
Previous Close
Day Range
7.2 7.71
Year Range
7.15 1,200
Want to track HSDT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 27 days
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

NEWTOWN, Pa., Oct. 18, 2024 – PRISM MediaWire – Helius Medical Technologies, Inc.

Prismmediawire | 9 months ago
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript

Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Michelle Bilski - IR Dane Andreeff - President and CO Jeff Mathiesen - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies Second Quarter 2024 Earnings Conference Call [Operator Instructions].

Seekingalpha | 11 months ago
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference

Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference

NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will participate in the Spring MicroCap Rodeo Conference to be held on Thursday, June 6th in NYC. Dane Andreeff, CEO, will attend the conference and plans to discuss: Pursuit of a stroke authorization in the U.S. for its Portable Neuromodulation Stimulator (PoNS®) device with the U.S. Food and Drug Administration (FDA); Helius' partnership with Lovell® Government Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD).

Accesswire | 1 year ago